eMedicine Specialties > Pediatrics: General Medicine > Infectious Disease

Lyme Disease: Follow-up

Author: Stephen C Aronoff, MD, Waldo E Nelson Chair and Professor, Department of Pediatrics, Temple University School of Medicine
Coauthor(s): Sarah L Wingerter, MD, Attending Physician, Department of Emergency Medicine, St Christopher's Hospital for Children; Clinical Assistant Professor of Pediatrics (Adjunct), Temple University School of Medicine
Contributor Information and Disclosures

Updated: Apr 17, 2009

Follow-up

Deterrence/Prevention

  • The best prevention for Lyme disease is education and awareness. Long pants and socks should be worn when in areas of likely tick exposure. Parents of children in endemic areas must be vigilant to check for ticks (especially the nymphs because of their smaller size) from the spring to the fall. Checking inside skin folds, behind ears, the umbilicus, groin, axilla, hairline, and scalp must be routine. Through education, parents can recognize early symptoms and signs.
  • Insecticides, sprayed on clothing or directly on the skin, can deter ticks, but use of these agents must be weighed against toxicity from overzealous application.
  • A Lyme disease vaccine was licensed by the US Food and Drug Administration (FDA) in 1998 but was subsequently withdrawn from the market in 2002 due to concerns regarding efficacy and side effects. The vaccine was made of recombinant outer surface protein A (OspA). Newer vaccines are in development.
  • Prophylactic antibiotics after any tick exposure are not recommended. Even in endemic areas, the risk of transmission from a tick is estimated to be only 1-2%. In hyperendemic areas, a single dose of doxycycline (adults) has been shown to decrease development of disease if given within 72 hours of tick bite.
  • Preventing exposure and removing ticks promptly is a much better strategy. However, in an endemic area, prolonged attachment, a concerned parent, or pregnancy may prompt consideration of prophylaxis or empiric treatment. For a known tick exposure, a thorough search for other ticks is necessary. Following discovery of an attached tick, education about symptoms and signs of Lyme disease is the most appropriate treatment.

Complications

  • One nonmedical complication of Lyme disease has been the public and media's misconceptions about the disease. Unfortunately, many clinicians perform too many tests when the prior probability of disease is low, resulting in many false-positive tests. The combination of nonspecific symptoms and suboptimal test results has led to overtreatment for suspected (but not proven) Lyme disease and to the concept of refractory Lyme disease. In endemic areas, some physicians have capitalized on the hysteria by offering nontraditional testing and treatment and fostering the notion that all ailments (behavioral, academic, medical) are related to the elusive spirochete.
  • The agents responsible for babesiosis and ehrlichiosis share the same tick vector as B burgdorferi, making co-infection possible. Acute infection caused by these agents is more common in asplenic individuals (babesiosis) or older adults (Ehrlichia); however, unlike B burgdorferi, chronic infection by these agents is not observed. To add to the confusion, ehrlichial infection may cause a false-positive result for Lyme disease on immunoglobulin M (IgM) Western blot analysis.

Prognosis

  • The prognosis of all stages of Lyme disease is excellent with appropriate antibiotic treatment. Symptoms of arthritis may persist for a few weeks beyond adequate therapy; therefore, retreatment usually is not necessary unless symptoms worsen or persist beyond 2 months.
  • Unfortunately, antibodies induced by the infection are not protective against further exposures to B burgdorferi; therefore, reinfection easily could be confused with a recurrence. Because antibodies may persist for years following an infection, repeat infection is a difficult diagnosis without specific signs of Lyme disease (eg, erythema migrans [EM] rash). Increasing titers after adequate treatment certainly raises suspicion of an active infection.
  • Some individuals with arthritis may have persistent symptoms after clearance of the infection. This phenomenon is most likely related to autoimmunity and is more prevalent among individuals with HLA-DR2, HLA-DR3, or HLA-DR4 allotypes.

Patient Education

Miscellaneous

Medicolegal Pitfalls

  • In the absence of specific signs, particularly in the early stage of infection, the diagnosis of Lyme disease can be difficult because of the limitations of current diagnostic tests.
  • Testing should be performed in patients with aseptic meningitis, facial nerve palsy, or arthritis for Lyme disease if they live in or have traveled to an endemic area.
  • Diagnosis of reinfection or recurrent infection is complicated by the persistence of antibody beyond the eradication of disease.
  • Because interpretation of testing is related to stage of disease and requires a 2-stage test, laboratory results are often misinterpreted. Clinicians unfamiliar with Lyme disease or Lyme testing may falsely exclude the diagnosis (early disease) or falsely diagnose disease (old antibody or using Western blot in those with negative enzyme-linked immunosorbent assay [ELISA] test results).
 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Richard G Bachur, MD and Marvin Harper, MD, to the original writing and development of this article.



More on Lyme Disease

Overview: Lyme Disease
Differential Diagnoses & Workup: Lyme Disease
Treatment & Medication: Lyme Disease
Follow-up: Lyme Disease
Multimedia: Lyme Disease
References
Further Reading

References

  1. Feder HM Jr. Lyme disease in children. Infect Dis Clin North Am. Jun 2008;22(2):315-26, vii. [Medline].

  2. Halperin JJ. Nervous system lyme disease: diagnosis and treatment. Rev Neurol Dis. Winter 2009;6(1):4-12. [Medline].

  3. Nigrovic LE, Thompson AD, Fine AM, Kimia A. Clinical predictors of Lyme disease among children with a peripheral facial palsy at an emergency department in a Lyme disease-endemic area. Pediatrics. Nov 2008;122(5):e1080-5. [Medline].

  4. Halperin JJ, Shapiro ED, Logigian E, Belman AL, Dotevall L, Wormser GP. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. Jul 3 2007;69(1):91-102. [Medline].

  5. The ILADS Working Group. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther. 2004;2(1 Suppl):S1-13.

  6. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. Nov 1 2006;43(9):1089-134. [Medline].

  7. Afzelius A. Erythema chronicum migrans. Acta Derm Venereol. 1921;2:120-125.

  8. Avery RA, Frank G, Glutting JJ, Eppes SC. Prediction of Lyme meningitis in children from a Lyme disease-endemic region: a logistic-regression model using history, physical, and laboratory findings. Pediatrics. Jan 2006;117(1):e1-7. [Medline].

  9. Christen HJ, Hanefeld F, Eiffert H, Thomssen R. Epidemiology and clinical manifestations of Lyme borreliosis in childhood. A prospective multicentre study with special regard to neuroborreliosis. Acta Paediatr Suppl. Feb 1993;386:1-75. [Medline].

  10. Cook SP, Macartney KK, Rose CD, Hunt PG, Eppes SC, Reilly JS. Lyme disease and seventh nerve paralysis in children. Am J Otolaryngol. Sep-Oct 1997;18(5):320-3. [Medline].

  11. Edlow JA. Lyme disease and related tick-borne illnesses. Ann Emerg Med. Jun 1999;33(6):680-93. [Medline].

  12. Gerber MA, Zemel LS, Shapiro ED. Lyme arthritis in children: clinical epidemiology and long-term outcomes. Pediatrics. Oct 1998;102(4 Pt 1):905-8. [Medline].

  13. Halsey NA, Abramson JS, Chesney PJ. American Academy of Pediatrics. Committee on Infecious Diseases. Prevention of Lyme disease. Pediatrics. Jan 2000;105(1 Pt 1):142-7. [Medline].

  14. Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: do additional antibiotics help?. Neurology. Jun 24 2003;60(12):1916-22. [Medline].

  15. Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. Jun 24 2003;60(12):1923-30. [Medline].

  16. Masuzawa T. Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis. Dec 2004;57(6):229-35. [Medline].

  17. Moses JM, Riseberg RS, Mansbach JM. Lyme disease presenting with persistent headache. Pediatrics. Dec 2003;112(6 Pt 1):e477-9. [Medline].

  18. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. Jul 12 2001;345(2):79-84. [Medline].

  19. Seltzer EG, Shapiro ED, Gerber MA. Long-term outcomes of lyme disease. JAMA. Jun 21 2000;283(23):3068-9. [Medline].

  20. Shapiro ED. Lyme disease. Pediatr Rev. May 1998;19(5):147-54. [Medline].

  21. Steere AC. Lyme borreliosis in 2005, 30 years after initial observations in Lyme Connecticut. Wien Klin Wochenschr. Nov 2006;118(21-22):625-33. [Medline].

  22. Steere AC. Lyme disease. N Engl J Med. Jul 12 2001;345(2):115-25. [Medline].

  23. Vázquez M, Sparrow SS, Shapiro ED. Long-term neuropsychologic and health outcomes of children with facial nerve palsy attributable to Lyme disease. Pediatrics. Aug 2003;112(2):e93-7. [Medline].

Keywords

lyme borreliosis, Borrelia burgdorferi, B burgdorferi, Ixodes scapularis, deer tick, tickbite, tick bite, tick-borne illness, Lyme arthritis, Lyme disease, Lyme meningitis, Ixodid ticks, erythema migrans, EM, aseptic meningitis, cranioneuropathies, Bell palsy, encephalitis, carditis, rash, treatment, diagnosis, skin rash, meningismus

Contributor Information and Disclosures

Author

Stephen C Aronoff, MD, Waldo E Nelson Chair and Professor, Department of Pediatrics, Temple University School of Medicine
Stephen C Aronoff, MD is a member of the following medical societies: Pediatric Infectious Diseases Society and Society for Pediatric Research
Disclosure: Nothing to disclose.

Coauthor(s)

Sarah L Wingerter, MD, Attending Physician, Department of Emergency Medicine, St Christopher's Hospital for Children; Clinical Assistant Professor of Pediatrics (Adjunct), Temple University School of Medicine
Sarah L Wingerter, MD is a member of the following medical societies: American Academy of Pediatrics
Disclosure: Nothing to disclose.

Medical Editor

Gary J Noel, MD, Department of Pediatrics, Clinical Associate Professor, Weill Medical College of Cornell University
Gary J Noel, MD is a member of the following medical societies: Pediatric Infectious Diseases Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus
Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

CME Editor

Robert W Tolan Jr, MD, Chief, Division of Allergy, Immunology and Infectious Diseases, The Children's Hospital at Saint Peter's University Hospital; Clinical Associate Professor of Pediatrics, Drexel University College of Medicine
Robert W Tolan Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Society for Microbiology, American Society of Tropical Medicine and Hygiene, Infectious Diseases Society of America, Pediatric Infectious Diseases Society, Phi Beta Kappa, and Physicians for Social Responsibility
Disclosure: GlaxoSmithKline Honoraria Speaking and teaching; MedImmune Honoraria Speaking and teaching; Merck Honoraria Speaking and teaching; sanofi pasteur Honoraria Speaking and teaching; Baxter Healthcare Honoraria Speaking and teaching

Chief Editor

Russell W Steele, MD, Head, Division of Pediatric Infectious Diseases, Ochsner Children's Health Center; Clinical Professor, Department of Pediatrics, Tulane University School of Medicine
Russell W Steele, MD is a member of the following medical societies: American Academy of Pediatrics, American Association of Immunologists, American Pediatric Society, American Society for Microbiology, Infectious Diseases Society of America, Louisiana State Medical Society, Pediatric Infectious Diseases Society, Society for Pediatric Research, and Southern Medical Association
Disclosure: None None None

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.